Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma

Gastrointestinal Stromal Tumor

Completed

2

Start Date 07/01/2015

Age of Trial (yrs) 9.4

Gleevec-resistant

PD-1 inhibitor + CTLA-4 inhibitor

Immunotherapy

Specifically GIST plus other cancers

NCI-2015-00260, NCI-2015-00260, A091401, A091401, U10CA180821

National Cancer Institute

Principal Investigator: Sandra P. D'Angelo Memorial Sloan-Kettering 212-639-7202

Randomized

Intravenous

There are over 500 sites listed as open across the US. Only major GIST centers are listed here. Check the Clinicaltrials.gov database for all potential sites and site contact information (621 listed across US).